Cebado cortical para optimizar la rehabilitación de la marcha en el ictus: una renovación
Cebado cortical para optimizar la rehabilitación de la marcha: Renovación
Achieving functional ambulation post stroke continues to be a challenge for stroke survivors, clinicians, and researchers. In the effort to enhance outcomes of motor training, cortical priming using brain stimulation has emerged as a promising adjuvant to conventional rehabilitation. This project focuses on the development of a long term gait rehabilitation protocol using brain stimulation to improve walking outcomes in people with stroke. The project will also aim to understand the neural mechanisms that are associated with response to the intervention.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- Physical Therapy
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age greater than 18 years
- First ever monohemispheric stroke > 3 months since onset
- Residual hemiparetic gait deficits (e.g. abnormal gait pattern)
- Able to walk for 5 minutes at self-paced speed. Handheld assistive device is acceptable.
- Walking speed lesser than 1.2 m/s
- Lower limb Fugl-Meyer Motor score between 15-30
- At least 5 deg of ankle dorsiflexion necessary to perform the ankle-tracking task
Exclusion Criteria:
-
General exclusion criteria
- Severe osteoporosis
- Contracture-limiting range of motion of lower limb
- Score of more than 2 on the Modified Ashworth Scale (indicating increased muscle tone through ankle range of motion)
- Uncontrolled anti-spasticity medications during the study period
- Score less than 6 on the Fugl-Meyer Sensory Assessment Scale for the Lower Limb
- Cardiorespiratory or metabolic diseases (e.g. cardiac arrhythmia, uncontrolled hypertension or diabetes, chronic emphysema)
- Unhealed decubiti, persistent infection
- Significant cognitive or communication impairment (Mini-Mental State Examination (MMSE)<21), which could impede the understanding of the purpose of procedures of the study or prevent the patient from performing the ankle-tracking task.
- Lesions involving the brainstem and cerebellum
- Failure to pass the graded exercise stress test
TMS exclusion criteria
- Implanted cardiac pacemaker
- Metal implants in the head or face
- Unexplained, recurring headaches
- History of seizures or epilepsy
- Currently under medication that could increase motor excitability and lower seizure threshold
- Skull abnormalities or fractures
- Concussion within the last 6 months
- Currently pregnant
tDCS exclusion criteria
- Skin hypersensitivity
- History of contact dermatitits
- History of allodynia and/or hyperalgesia
- Any other skin or scalp condition that could be aggravated by tDCS
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Priming+HIISTT
Facilitatory transcranial direct current stimulation (tDCS) and ankle motor training before high intensity interval speed based treadmill training |
1 mA tDCS Visuomotor target tracking task Each treadmill session to include warm-up, high intensity speed-based intervals interleaved with active recovery, and cool down. |
|
Comparador falso: Sham+HIISTT
Sham tDCS before high intensity interval speed based treadmill training |
Each treadmill session to include warm-up, high intensity speed-based intervals interleaved with active recovery, and cool down. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Walking speed with 10 meter walk test
Periodo de tiempo: Change from baseline to immediately after training and baseline to 3 months follow up
|
Self-selected and fastest gait speed will be measured as the average of 3 trials of the 10-m walk test (10MWT). |
Change from baseline to immediately after training and baseline to 3 months follow up
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Walking spatiotemporal characteristics with GAITRite walkway
Periodo de tiempo: Change from baseline to immediately after training and baseline to 3 months follow up
|
Spatiotemporal parameters of walking will be assessed using a 7m long pressure sensitive mat (GAITRite walkway). |
Change from baseline to immediately after training and baseline to 3 months follow up
|
|
Motor impairment with Fugl Meyer Lower Extremity Scale
Periodo de tiempo: Change from baseline to immediately after training and baseline to 3 months follow up
|
Lower extremity impairment will be measured using the Fugl Meyer Lower Extremity Scale (FMLE), a series of tests of movement, reflex activity, coordination/speed, sensation, and range of motion. The maximum score is 34 and a high score indicates less impairment |
Change from baseline to immediately after training and baseline to 3 months follow up
|
|
Walking endurance with 6-minute walk test
Periodo de tiempo: Change from baseline to immediately after training and baseline to 3 months follow up
|
Walking endurance will be measured using the 6-Minute Walk test. Participants will walk as far as possible within 6 minutes. |
Change from baseline to immediately after training and baseline to 3 months follow up
|
|
Ankle range of motion
Periodo de tiempo: Change from baseline to immediately after training and baseline to 3 months follow up
|
Ankle range of motion will be measured using a wireless electrogoniometer affixed to the ankle. |
Change from baseline to immediately after training and baseline to 3 months follow up
|
|
Ankle motor control
Periodo de tiempo: Change from baseline to immediately after training and baseline to 3 months follow up
|
The participant will track a computer-generated sinusoidal target with ankle dorsiflexion and plantarflexion in a custom-built ankle-tracking device. Accuracy of tracking the target with ankle motion will be calculated. |
Change from baseline to immediately after training and baseline to 3 months follow up
|
|
Balance with mini Balance Evaluations Systems Test (miniBESTest)
Periodo de tiempo: Change from baseline to immediately after training and baseline to 3 months follow up.
|
Balance will be tested with the Mini-BESTest, involving 14 different tasks to challenge balance. |
Change from baseline to immediately after training and baseline to 3 months follow up.
|
|
Aerobic capacity
Periodo de tiempo: Change from baseline to immediately after training.
|
Cardiopulmonary exercise tests will be performed on a motorized treadmill following an individualized protocol using standard procedures. Measures relating to peak oxygen consumption (VO2 max) will be calculated. |
Change from baseline to immediately after training.
|
|
Quality of Life with EuroQol-5D (EQ-5D)
Periodo de tiempo: Change from baseline to immediately after training.
|
Quality of life will be measured with the EuroQol-5D (EQ-5D), a questionnaire with questions designed to assess aspects of quality of life. |
Change from baseline to immediately after training.
|
|
Disability with Modified Rankin Scale
Periodo de tiempo: Change from baseline to immediately after training and baseline to 3 months follow up.
|
Global disability will be measured with the modified Rankin Scale, a simple 0-6 rating scale. |
Change from baseline to immediately after training and baseline to 3 months follow up.
|
|
Community ambulation with wearable sensors
Periodo de tiempo: Change from baseline to immediately after training.
|
Daily ambulation will be assessed using an accelerometer. |
Change from baseline to immediately after training.
|
|
Serum brain derived neurotrophic growth factor (BDNF)
Periodo de tiempo: Change from baseline to immediately after training.
|
5 ml of blood will be collected from a vein in the participants' arms |
Change from baseline to immediately after training.
|
|
Corticomotor excitability using transcranial magnetic stimulation
Periodo de tiempo: Change from baseline to immediately after training and baseline to 3 months follow up.
|
Corticomotor excitability of the paretic and non-paretic lower limb muscles such as the tibialis anterior and soleus muscle representations will be measured with single pulse transcranial magnetic stimulation (TMS). |
Change from baseline to immediately after training and baseline to 3 months follow up.
|
|
Cognitive function using Mini Mental Screening Examination
Periodo de tiempo: Change from baseline to immediately after training and baseline to 3 months follow up.
|
30-point questionnaire used to capture orientation, attention, memory and language. |
Change from baseline to immediately after training and baseline to 3 months follow up.
|
|
Depression using Patient Health Questionnaire-9 (PHQ-9)
Periodo de tiempo: Change from baseline to immediately after training and baseline to 3 months follow up.
|
The 9-point questionnaire is used to measure degree of depression. |
Change from baseline to immediately after training and baseline to 3 months follow up.
|
|
Modified Ashworth Scale
Periodo de tiempo: Change from baseline to immediately after training and baseline to 3 months follow up.
|
The modified Ashworth scale is a muscle tone assessment scale used to assess the resistance experienced during passive range of motion, |
Change from baseline to immediately after training and baseline to 3 months follow up.
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Sangeetha Madhavan, University of Illinois Chicago
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Trastornos cerebrovasculares
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Carrera
- Terapéutica
- Disciplinas y actividades de comportamiento
- Terapia de estimulación eléctrica
- Terapia convulsiva
- Terapias somáticas psiquiátricas
- Electrochoque
- Técnicas psicológicas
- Estimulación de corriente continua transcraneal
Otros números de identificación del estudio
Otros números de identificación del estudio
- 2020-0502
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .